Business Context and Reporting Period
This Form 8-K is a current report filed by Integrity Applications, Inc. (not Glucotrack, Inc., as noted in the metadata) on December 31, 2014. The filing discloses the entry into a material definitive agreement regarding the final closing of a private placement offering of securities.
Key Financial Metrics and Transaction Details
- Proceeds Raised: The Company received aggregate proceeds of $1,647,455 from the sale of 1,647.45 Units in this closing.
- Securities Issued: Each Unit consists of one share of Series B 5.5% Convertible Preferred Stock and two warrants (Series B-1 and Series B-2).
- Conversion and Exercise Terms:
- Preferred Stock converts to Common Stock at an initial price of $5.80 per share.
- Series B-1 Warrants: 5-year term, exercise price of $5.80.
- Series B-2 Warrants: 5-year term, exercise price of $10.00.
- Dilution Potential: The Preferred Stock in this closing is convertible into 284,056 shares of Common Stock. The Warrants are exercisable for 568,114 shares of Common Stock.
- Placement Agent Compensation: The Company paid a commission of 7%, a management fee of 3%, and a non-accountable expense allowance of 3% of the aggregate sales price. Additionally, the agent received warrants to purchase 56,812 shares at $5.80 and 28,406 shares at $10.00.
Material Changes and Offering Status
This transaction represents the fourth and final closing of the offering. Previous closings occurred on September 5, October 6, and November 6, 2014, involving the sale of 3,036, 2,541.6, and 1,274.95 Units, respectively. The terms of the securities issued in this final closing are identical to those in the prior closings.
Guidance, Risks, and Unusual Items
- Unregistered Sale: The Units were sold without registration under the Securities Act of 1933, relying on the Section 4(a)(2) exemption for transactions by an issuer not involving any public offering. They were offered only to accredited investors.
- Registration Rights: A Registration Rights Agreement was entered into, substantially identical to agreements with prior purchasers, granting rights to register the securities for public sale.
- Management Commentary: The filing contains no forward-looking guidance, revenue projections, or management commentary regarding operational performance or future outlook.
Investor Verification Checklist
- Verify the total capital raised across all four closings of this offering to assess total liquidity impact.
- Confirm the total number of shares of Common Stock issuable upon full conversion of all Series B Preferred Stock and exercise of all warrants issued in this offering series.
- Review the prior 8-K filings (Sept 5, Oct 6, Nov 6, 2014) to understand the full scope of the offering and any changes in investor composition.
- Assess the dilution impact of the placement agent warrants (85,218 total shares) in addition to investor warrants.
- Note that the filing text does not provide current revenue, profit, cash flow, or debt levels; these metrics are not disclosed in this specific 8-K.